The Apple Watch Oxygen Sensor Lawsuit: Understanding the Claims, Impacts, and Your Options (Updated July 2024)

The Core Issue: Apple currently faces an ongoing patent infringement lawsuit brought by medical technology company Masimo Corporation, primarily targeting the blood oxygen monitoring (SpO2) sensor technology used in Apple Watch Series 6, 7, 8, 9, and Ultra (all non-U.S. models sold since January 2024 have this hardware feature disabled). The U.S. International Trade Commission (ITC) ruled that Apple infringed on Masimo patents, resulting in a U.S. import ban on watches featuring the active sensor. While Apple implemented a software workaround (disabling the feature on new U.S. sales) to comply with the ban, older models with the active feature remain widely used, and the core patent dispute is still pending in U.S. federal court. Masimo also directly competes with Apple in the consumer health wearable market.

(This initial paragraph concisely states the current core situation – the lawsuit (Masimo vs. Apple), the specific technology involved (SpO2 sensor), the ITC ruling and import ban consequence, Apple's response (software disablement), the state of the federal case, and the competitive landscape. Subsequent sections will break down each aspect in detail.)

What Does the Apple Watch Blood Oxygen Sensor Actually Do?

The Blood Oxygen app on affected Apple Watch models uses a technology called optical oximetry. This involves shining red and infrared LED lights onto the skin and underlying blood vessels at your wrist. Photodiodes then measure the amount of light reflected back. Oxygen-rich blood (oxyhemoglobin) absorbs more infrared light and allows more red light to pass through. Oxygen-poor blood (deoxyhemoglobin) absorbs more red light and allows more infrared light to pass through. By analyzing these light absorption patterns, the sensor calculates the percentage of oxygen-saturated hemoglobin in your blood – your SpO2 level.

Apple clearly markets this feature as being "only designed for general fitness and wellness purposes," not for medical diagnosis or monitoring medical conditions. Results are presented with a disclaimer stating they "aren't intended for medical use." Typical readings range from about 95% to 100% for healthy individuals at sea level, though variations can occur. The app allows users to take spot checks manually or configure background readings during sleep.

Masimo's Core Allegations Against Apple

Masimo, a long-established leader in clinical-grade pulse oximetry used in hospitals worldwide, alleges that Apple willfully infringed on several of its patented technologies related to light-based blood constituent monitoring. Key aspects of Masimo's lawsuit, filed in the U.S. District Court for the Central District of California in June 2021, include:

  1. Patent Infringement: Masimo holds numerous patents covering innovations in non-invasive optical sensors, signal processing algorithms, and device designs specifically for measuring blood oxygen and other blood constituents. The lawsuit details specific claims from multiple patents (e.g., US Patent Nos. 10,687,745; 10,945,648; 7,215,984; 7,761,150) that it alleges Apple incorporated into its SpO2 sensor technology without permission or license.
  2. Trade Secret Misappropriation: Masimo further alleges that Apple engaged in discussions about a potential partnership or acquisition starting around 2013. During these talks, Masimo claims it shared confidential technical information about its sensor technology. Masimo contends Apple used this proprietary information to develop its competing Apple Watch SpO2 sensor after acquisition talks ultimately failed. This adds a significant layer beyond just patent infringement.
  3. Unfair Competition & Hiring Key Employees: The complaint also details Apple's hiring of key Masimo personnel, including Masimo’s Chief Medical Officer (Michael O’Reilly) and a key technical executive involved with Masimo’s wearable projects (Cercacor is Masimo's consumer spin-off). Masimo argues this was a coordinated effort to gain access to its trade secrets and technical expertise to fast-track Apple's own wearable health monitoring development.
  4. Direct Competitor Harm: Masimo emphasizes that it launched its own consumer wearable, the Masimo W1, which directly incorporates its patented SpO2 technology and competes in the same market space as the Apple Watch. Masimo asserts Apple's alleged infringement has caused significant harm to its consumer business.

The ITC Ruling and Its Immediate U.S. Impact

Parallel to the federal court case, Masimo also pursued an action against Apple at the U.S. International Trade Commission (ITC) under Section 337, focusing on patent infringement claims related to the SpO2 sensor's hardware and software.

  • Initial Finding: In October 2023, the ITC Administrative Law Judge (ALJ) issued an initial determination finding that Apple had indeed infringed upon two specific Masimo patents related to light-based oximetry and components.
  • ITC Commission Decision: In late December 2023, the full ITC Commission largely upheld the ALJ's findings of infringement on some claims of the patents under investigation. Crucially, the ITC issued a Limited Exclusion Order and a Cease and Desist Order.
    • Limited Exclusion Order: Banned the importation into the United States of Apple Watches models identified in the orders that contain the infringing SpO2 sensor technology. This primarily targeted Apple Watch Series 9 and Ultra 2 models being shipped into the U.S. after the ruling's effective date.
    • Cease and Desist Order: Prohibited Apple from selling or distributing within the United States any infringing Apple Watch devices that were already imported and in its U.S. inventory at the time of the ruling.
  • Presidential Review & Final Ban: The ruling went through a mandatory 60-day Presidential Review period. The Biden Administration declined to veto the ITC's decision. Consequently, on December 26, 2023, the import ban came into effect.
  • Apple's Immediate Response - Software Workaround: Faced with the import ban halting sales of its flagship watches in the U.S., Apple urgently implemented a software solution. It released watchOS updates (starting with watchOS 10.3 in January 2024) that disabled the Blood Oxygen app and underlying SpO2 measurement hardware functionality on newly sold Apple Watch Series 9 and Ultra 2 units within the U.S.
    • Purpose: This software disablement allowed Apple to resume importing and selling these models in the U.S. market immediately, as the physical sensor hardware itself, while present, was rendered inactive and non-infringing. The ITC confirmed in January 2024 that Apple's redesigned products (i.e., watches with the feature disabled) were no longer covered by the exclusion order.
    • Consumer Impact: Models purchased before late December 2023/early January 2024 in the U.S. were not affected by this software disablement and retained full SpO2 functionality if they already had it. Only brand new U.S. purchases after the software disablement update started shipping have the feature disabled entirely. Pre-owned U.S. models purchased earlier with the feature enabled also retain it. Watches purchased outside the U.S. are completely unaffected by the ban and feature disablement.

The Ongoing Federal Lawsuit: Seeking Damages

While the ITC action addressed importation and sale bans, the central legal battle over the patent infringement and trade secret claims continues in the U.S. District Court for the Central District of California (Case No.: 8:20-cv-00048). This case is fundamentally about monetary damages and liability:

  1. Objective: Masimo is seeking significant financial compensation for Apple's alleged infringement of its patents and misappropriation of its trade secrets. The potential damages could amount to hundreds of millions, or even billions, of dollars, calculated based on Apple's sales of the infringing watches.
  2. Status: The case is progressing through the complex pre-trial discovery and motion phases. Both sides are exchanging evidence, taking depositions, and filing legal arguments. A trial date has not yet been set as of July 2024.
  3. Apple's Defense: Apple vehemently denies Masimo's allegations. It argues that it independently developed its SpO2 technology without utilizing Masimo's confidential information or infringing on its valid patents. Apple maintains that its technology is distinct and may also challenge the validity of Masimo's patents in court.
  4. Counterclaims: In response to Masimo's lawsuit, Apple has filed counterclaims against Masimo. It alleges Masimo is attempting to stifle competition by leveraging its patent portfolio improperly against Apple's successful wearable. Apple may also target Masimo's W1 watch.

What Does This Mean for Current Apple Watch Users?

  1. U.S. Users With Pre-Ban Watches: If you purchased an Apple Watch Series 6, 7, 8, 9, or Ultra within the U.S. BEFORE late December 2023 / early January 2024 and it shipped with SpO2 functionality enabled, your Blood Oxygen app continues to work normally. Apple's compliance software updates do not disable the feature on these existing devices. You retain the full SpO2 monitoring capability your watch originally had.
  2. U.S. Users Purchasing After the Ban/Software Update: If you buy a brand new Apple Watch Series 9 or Ultra 2 within the U.S. from Apple or authorized retailers after Apple began shipping the hardware-disabled models (starting mid-January 2024), your watch will NOT have the Blood Oxygen app at all, and the underlying sensor hardware is disabled. You cannot activate or use this feature. The hardware chip is present but inactive via software. The hardware icon/lens remains on the watch back. Older models (SE, Series 4, Series 5) never had the sensor.
  3. Users Outside the United States: The ITC ruling and Apple's software disablement have NO impact whatsoever on Apple Watch models sold outside the U.S. Blood Oxygen monitoring remains fully functional on all applicable Apple Watch models (Series 6, 7, 8, 9, Ultra, Ultra 2) purchased internationally, both before and after the January 2024 U.S. changes.
  4. Potential Future Updates: Should Apple resolve the patent dispute (e.g., through a settlement, licensing agreement, or victory in court), there remains a theoretical possibility that it could reactivate the SpO2 feature on U.S. watches sold post-ban via a future software update. However, Apple has made no promises or announcements suggesting this will happen. It is equally possible the feature remains permanently disabled on those specific U.S. units regardless of the lawsuit outcome.

Implications Beyond Apple and Masimo

  1. Consumer Choice and Product Value: The lawsuit and its outcome directly impact the features available to consumers in the crucial U.S. market. While Apple Watches offer numerous other functions, the removal of SpO2 monitoring reduces the feature set for new U.S. buyers compared to international customers and owners of pre-ban U.S. watches. This creates a feature disparity.
  2. The High Stakes of Innovation in Wearables: The case highlights the fiercely competitive nature of the health tech and wearables market. Established medical device companies with large patent portfolios (like Masimo) and tech giants entering the health sector (like Apple) are increasingly clashing. Protection of intellectual property is paramount.
  3. Clash Between Medical Tech and Consumer Tech Standards: The dispute underscores the tension between highly regulated, rigorously validated medical device development cycles and the faster-paced consumer electronics market. Consumers often conflate wellness data with medical-grade data, and the lawsuit brings the distinction into sharper focus. It raises questions about the accuracy and reliability thresholds expected for features promoted in consumer devices.
  4. Impact on Clinical Trials and Research: Some ongoing clinical research studies relied on Apple Watch's SpO2 sensor for large-scale data collection (e.g., tracking recovery post-COVID, identifying sleep apnea indicators). The feature disruption in new U.S. watches could affect the continuity and scope of such research using Apple's platform in the U.S.
  5. Potential Future Legal Landscape: A victory for Masimo, particularly on the trade secret front, could embolden other medical tech companies to pursue similar actions against tech entrants perceived to be infringing on core health monitoring patents. Conversely, an Apple victory might reinforce its strategy of integrating advanced health features. Broader industry patent licensing dynamics could also shift based on the outcome.

What Should Consumers Do Now?

  1. Understand Your Device: Be aware of whether your specific Apple Watch model supports SpO2 monitoring and whether your unit is affected by the U.S. ban software disablement. Check your Apple Watch app or settings for the Blood Oxygen app icon. If you purchased a Series 9 or Ultra 2 in the U.S. after January 15, 2024, and the app isn't present, the feature is disabled. If you have an older model (Series 6, 7, 8, 9 or Ultra purchased in the U.S. before late Dec 2023) or any model purchased internationally, the feature is present and active (if the model supports it).
  2. Recognize Feature Limitations: Remember that Apple's Blood Oxygen feature, even when functional, is a wellness tool designed for "general fitness and wellness purposes." It is not a medical device. Do not rely on its readings for diagnosing, treating, or managing any health condition. Significant drops in SpO2, persistent low readings, or symptoms like shortness of breath warrant consulting a qualified healthcare professional, regardless of what your watch shows. Clinical pulse oximeters used in medical settings undergo far more rigorous validation and calibration.
  3. For New U.S. Buyers Needing SpO2: If having an on-wrist SpO2 sensor is an important factor for you and you are buying new in the U.S., consider:
    • Purchasing a pre-owned Apple Watch Series 6, 7, 8, or pre-ban Series 9/Ultra that still has the feature enabled (confirm this before purchase).
    • Exploring third-party wearables that offer SpO2 monitoring (like Fitbit Sense series, Samsung Galaxy Watch series, Withings ScanWatch, Garmin Venu/Vivoactive/Forerunner/Fenix/Instinct series, or Masimo's own W1).
    • Purchasing an Apple Watch internationally (though consider warranty and cellular compatibility).
    • Using a standalone FDA-cleared pulse oximeter for spot checks, recognizing it too has limitations without medical context.
  4. Stay Informed: The federal lawsuit is expected to continue for some time. Reliable technology news sources and legal reporters covering intellectual property will provide updates on significant developments.

Conclusion: A Complex Battle Reshaping the Wearable Market

The Apple Watch oxygen sensor lawsuit is a multifaceted conflict, intertwining patent law, trade secrets, corporate competition, and product design. Masimo's aggressive legal strategy successfully halted the import and sale of new Apple Watches with active SpO2 sensors in the U.S., forcing Apple to disable the feature on new domestic units. However, the dispute over damages and the underlying patent/trade secret claims rages on in federal court. For consumers, the outcome affects both the features available on future Apple Watches and the competitive landscape for health-focused wearables. While existing U.S. users of older watches retain their SpO2 feature and international users remain unaffected, new buyers in the U.S. face a reduced feature set as the legal battle unfolds. The case underscores the intense battle for market share and intellectual property dominance in the rapidly evolving wearable health tech sector. The final resolution will have lasting implications for the products on our wrists and the strategies companies employ to bring health features to market.

Back to blog